donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > FGEN FibroGen > Detailed Quotes

FGEN FibroGen

11.400
+0.840+7.95%
Close 07/01 16:00 ET
11.40000.00%
Post Mkt Price 07/01 16:59 ET
High
11.550
Open
10.710
Turnover
8.45M
Low
10.490
Pre Close
10.560
Volume
751.74K
Market Cap
1.06B
P/E(TTM)
Loss
52wk High
27.550
Shares
93.30M
P/E(Static)
Loss
52wk Low
7.810
Float Cap
923.88M
Bid/Ask %
60.00%
Historical High
68.550
Shs Float
81.04M
Volume Ratio
0.88
Historical Low
7.810
Dividend TTM
--
Div Yield TTM
1000
P/B
6.73
Dividend LFY
--
Div Yield LFY
8771.93%
Turnover Ratio
0.93%
Amplitude
10.04%
Avg Price
11.238
Lot Size
1
Float Cap
923.88M
Bid/Ask %
60.00%
Historical High
68.550
Shs Float
81.04M
Volume Ratio
0.88
Historical Low
7.810
Dividend TTM
--
P/B
6.73
Dividend LFY
--
Turnover Ratio
0.93%
Amplitude
10.04%
Avg Price
11.238
Lot Size
1
Price Forecast

No Data

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
CEO: Conterno, Enrique A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...